Squarepoint
ALBO

Squarepoint’s Albireo Pharma Inc ALBO Stock Holding History

Squarepoint’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,061
Closed -$311K – 3743
2022
Q3 		$311K Buy
+16,061
New +$332K ﹤0.01% 2462
2021
Q4 		– Sell
-25,601
Closed -$799K – 3649
2021
Q3 		$799K Buy
25,601
+8,144
+47% +$252K ﹤0.01% 1698
2021
Q2 		$614K Buy
17,457
+10,399
+147% +$338K ﹤0.01% 1992
2021
Q1 		$249K Buy
+7,058
New +$261K ﹤0.01% 2554
2020
Q4 		– Sell
-9,448
Closed -$315K – 3375
2020
Q3 		$315K Sell
9,448
-362
-4% -$10.5K ﹤0.01% 1758
2020
Q2 		$260K Buy
+9,810
New +$231K ﹤0.01% 1693
2020
Q1 		– Sell
-22,017
Closed -$560K – 2721
2019
Q4 		$560K Sell
22,017
-200
-0.9% -$4K ﹤0.01% 1705
2019
Q3 		$444K Buy
22,217
+14,701
+196% +$381K ﹤0.01% 1678
2019
Q2 		$242K Buy
+7,516
New +$251K ﹤0.01% 2029

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Squarepoint's ALBO Position: Q4 2022 in Review

Squarepoint sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 16,061 shares — an estimated $311K sold.

Squarepoint first reported a position in ALBO in Q2 2019 and held it in 9 quarters. The position peaked at $799K in Q3 2021. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Squarepoint reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Squarepoint sold 16,061 Albireo Pharma Inc shares in Q4 2022, an estimated $311K.
  • Squarepoint first reported a position in Albireo Pharma Inc in Q2 2019 and held it in 9 quarters.
  • Squarepoint's Albireo Pharma Inc position peaked at $799K in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Squarepoint's 13F filing for Q4 2022, filed 14 Feb 2023.